Cargando…
Huashi baidu granule in the treatment of pediatric patients with mild coronavirus disease 2019: A single-center, open-label, parallel-group randomized controlled clinical trial
Background: Since late February 2022, a wave of coronavirus disease 2019 (COVID-19) mainly caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant rapidly appeared in Shanghai, China. Traditional Chinese medicine treatment is recommended for pediatric patients; how...
Autores principales: | Chen, Jiande, Tang, Qiuyu, Zhang, Baoqin, Yuan, Shuhua, Chen, Jia, Shen, Shiyu, Wang, Dong, Lin, Jilei, Dong, Hongliang, Yin, Yong, Gao, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892187/ https://www.ncbi.nlm.nih.gov/pubmed/36744267 http://dx.doi.org/10.3389/fphar.2023.1092748 |
Ejemplares similares
-
Efficacy and Safety of Huashi Baidu Granules in Treating Patients with SARS-CoV-2 Omicron Variant: A Single-Center Retrospective Cohort Study
por: Chen, Cai-yu, et al.
Publicado: (2023) -
Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods
por: Zhu, Yi-Wei, et al.
Publicado: (2021) -
Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19
por: Xu, Haiyu, et al.
Publicado: (2023) -
Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS
por: WEI, Wen-Long, et al.
Publicado: (2021) -
The therapeutic efficacy of Huashi Baidu Formula combined with antiviral drugs in the treatment of COVID-19: A protocol for systematic review and meta-analysis
por: Han, Lizhu, et al.
Publicado: (2020)